- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01301755
Diagnosis of Invasive Pulmonary Aspergillosis by Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate by Ultrasound-guided Fine Needle Aspiration
Invasive aspergillosis is a serious and often fatal infection in patients who are neutropenic or have undergone solid organ or stem cell transplantation. However, early diagnosis of invasive aspergillosis is a challenge. Reiss and Lehmann first described the value of serum Galactomanna (GM) for diagnosis of invasive pulmonary aspergillosis in 1979. The availability of the Platelia Aspergillus, a sandwich ELISA that has been approved by FDA in 2003 for managing patients at risk of invasive aspergillosis because of the early detection of the GM antigen. In several studies so far the specificity of the serum galactomannan assay was greater than 85%; however, variable sensitivity from 29~100% was noted over years. In addition, low values and false-negative results are seen more often in nonneutropenic and solid organ transplantation patients as opposed to severely granulocytopenic patients .There are several factors that might explain the reported difference in the performance of antigen detection, including the biological factors and epidemiological factors.
In recent years, specimens of other body fluids are increasingly used for detection of Aspergillus galactomannan antigen, including urine, bronchoalveolar lavage(BAL) fluid, cerebrospinal fluid and even the tissue specimen. However, the sensitivity and specificity of the GM detection in various specimens still have considerably variation. Ultrasound-guided transthoracic aspirate is a safe and useful method for collecting specimens for accurate bacteriologic diagnosis of lung abscess and obstructive pneumonitis10. We also reported a study of diagnosis of pulmonary Cryptococosis by ultrasound guided percutaneous aspiration. We plan to perform a prospective single-center study to investigate the role of GM in the target organ (lung tissue/fluid) by using ultrasound-guided fine needle aspirate for early diagnosis invasive aspergillosis compared with the serum galactomannan.
Study Overview
Detailed Description
Invasive aspergillosis is a serious and often fatal infection in patients who are neutropenic or have undergone solid organ or stem cell transplantation. However, early diagnosis of invasive aspergillosis is a challenge. Reiss and Lehmann first described the value of serum Galactomanna (GM) for diagnosis of invasive pulmonary aspergillosis in 1979. Galactomannan is a water-soluble, polysaccharide cell wall component which is released by Aspergillus during fungal growth after inhalation of Aspergillus conidia to the lung. The availability of the Platelia Aspergillus, a sandwich ELISA that has been approved by FDA in 2003 for managing patients at risk of invasive aspergillosis because of the early detection of the GM antigen. In several studies so far the specificity of the serum galactomannan assay was greater than 85%; however, variable sensitivity from 29~100% was noted over years. In addition, low values and false-negative results are seen more often in nonneutropenic and solid organ transplantation patients as opposed to severely granulocytopenic patients .There are several factors that might explain the reported difference in the performance of antigen detection, including the biological factors (non-neutropenic patients, prior exposure to antifungal agents, encapsulation abscess preventing GM leakage to the circulation, renal clearance,…etc.) and epidemiological factors (patient population, cut-off value, prevalence of infection…etc) .
In recent years, specimens of other body fluids are increasingly used for detection of Aspergillus galactomannan antigen, including urine, bronchoalveolar lavage(BAL) fluid, cerebrospinal fluid and even the tissue specimen. However, the sensitivity and specificity of the GM detection in various specimens still have considerably variation. Ultrasound-guided transthoracic aspirate is a safe and useful method for collecting specimens for accurate bacteriologic diagnosis of lung abscess and obstructive pneumonitis10. We also reported a study of diagnosis of pulmonary Cryptococosis by ultrasound guided percutaneous aspiration. We plan to perform a prospective single-center study to investigate the role of GM in the target organ (lung tissue/fluid) by using ultrasound-guided fine needle aspirate for early diagnosis invasive aspergillosis compared with the serum galactomannan.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Hao-Chien Wang
- Phone Number: 0972651872
- Email: haochienwang@gmail.com
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Hao-Chien Wang
- Phone Number: 0972651872
- Email: haochienwang@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Eligible patients with following host factors:
- A hematologic malignancy, unless they were already treated with antifungals for a presumed or proven IA
- Cancer and receiving chemotherapy within the last 3 months before admission
- Solid organ transplant recipient
- Prolong steroid use
- Recipient of any other immunosuppressive treatment (tacrolimus, cyclosporine, methotrexate, cyclophosphamide, sirolimus)
- Child C cirrhosis
- HIV
- Febrile neutropenia
Combined at least two of the three following features:
- Fever(>37.5。C) refractory to at least 3 days of appropriate antibiotics or Fever relapsing after a period of defervescence of at least 48 hours while still receiving antibiotics
- Clinical signs and/or symptoms suggestive of invasive mycosis: pleuritic chest pain or physical finding of pleural rub, or one of the following symptoms of lower respiratory tract infection (new sputum secretions, dypsnea, or hemoptysis)
- Development of new pulmonary infiltrates on chest X-ray or HRCT
Exclusion Criteria:
- Patients who can't be cooperative
- Have bleeding tendency or coagulopathy (PLT<100K)
- Pulmonary lesion could not identify by chest ultrasonography
- Patients who do not have informed consent before the procedure
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
|
direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The diagnostic rate of lung tissue Aspergillus galactomannan antigen detection compaired with serum Aspergillus galactomannan antigen detection
Time Frame: 3 weeks
|
we will use echo-guide lung tissue aspiration to detect lung tissue Aspergillus galactomannan antigen compaired with conventional serum Aspergillus galactomannan antigen detection to early diagnose pulmonary aspergillosis
|
3 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hao-Chien Wang, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201002035R
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunocompromised
-
Children's Hospital Medical Center, CincinnatiAstellas Pharma IncTerminatedCancer | Immunocompromised | Bone Marrow TransplantUnited States
-
HepNet Study House, German LiverfoundationCompletedImmunocompromised | TransplantedGermany
-
HepNet Study House, German LiverfoundationTerminated
-
University Hospital, LilleCompletedCritical Care | Immunocompromised HostFrance
-
Assistance Publique - Hôpitaux de ParisRecruitingImmunocompromised PatientsFrance
-
Groupe Hospitalier Paris Saint JosephCompletedImmunocompromised Patients and Non-immunosuppressed Patients at Risk With an Indication for Pneumococcal VaccinationFrance
-
Fundação Bahiana de InfectologiaCompletedSeverely Immunocompromised HIV PatientsBrazil
-
Heidelberg UniversityUnknownAspergillosis | Infection in an Immunocompromised HostGermany
-
Brynn ChappellThe Christie NHS Foundation TrustSuspendedAspergillosis | Immunocompromised Patient | FusariumUnited Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | ImmunocompromisedUnited States
Clinical Trials on Lung aspiration
-
RapidPulse, IncRecruiting
-
Cedars-Sinai Medical CenterRecruiting
-
The Young Investigator Group of Cardiovascular...SuspendedCoronary Artery Disease | ST Elevation Myocardial Infarction | Percutaneous Coronary InterventionEgypt
-
University Medical Centre LjubljanaBlood Transfusion Centre of SloveniaRecruitingOsteoarthritis, KneeSlovenia
-
RapidPulse, IncNot yet recruiting
-
RapidPulse, IncNot yet recruitingStroke | Acute Ischemic Stroke | Large Vessel Occlusion | Mechanical ThrombectomyGeorgia
-
RapidPulse, IncCompletedAcute Ischemic StrokeDenmark, Latvia, Turkey, Brazil, Spain
-
Fisiatria y TraumatologíaAmerican Association of Orthopaedic MedicineCompletedOsteoarthritis, KneeArgentina
-
Yokohama City University Medical CenterTeikyo UniversityCompleted
-
Assistance Publique - Hôpitaux de ParisWithdrawn